He is a bitter ex-long that sold at the bottom. I saw his post. He also unfortunately achieved his desired results with you - putting seeds of doubts in your mind. So he does know the company to a degree. Please don't take it personal. Imagine the seeds of doubt I've had being a stockholder and adding over the years since late 2011. I chuckled when I saw his post regarding a r/s. A secondary, they have said they have money to mid 2016. With these additional P1's that will fire up from the recently announced joint venture, I believe you can use your common sense that they will have to raise additional monies at some point. Last I looked you have to spend it to make it. Personally I don't have a problem with it if you're executing your business plan being a 26 year business owner. If you've been around you know many secondaries are gobbled right up when the story is good. As I said in the previous post, I feel in the next 45 days there will be continuing increased visibility how things are progressing. Also as I said previously I want that IPF trial to resume and that is out of their hands. It had just begun when Roche halted it to rework the trial. I'd like to think by midyear at the latest. And it wouldn't hurt to hear the royalty rate for Erivedge went up a 1/2% or 1% now that it hit $140M in annual sales. :) The best laugh I had this weekend was an obvious short at Twitter that reached out to Jim Cramer about Curis. :)))
News 
Market Data 
Discover 
